Lorlatinib was found to have not only extracranial but also intracranial activity in other ALK TKIs, including second-generation ALK TKIs, in refractory patients with ALK-rearranged NSCLC with or without CNS metastases (mPFS = 6.6 mo, ORR = 39.6%, intracranial ORR = 56.1%).11 This evidence concerns the gene ALK and non-small cell lung carcinoma.